20-F: CureVac Restructures Collaboration with GSK, Focuses on Oncology and Infectious Diseases

CureVac restructures its collaboration with GSK into a licensing agreement, granting GSK full control over influenza and COVID-19 vaccine development while CureVac focuses on oncology and other areas.

Summary

• CureVac restructured its collaboration with GSK, granting GSK full control over influenza and COVID-19 vaccine development.
• CureVac received a 400 million upfront payment and is eligible for up to 1.05 billion in milestones plus tiered royalties.
• The company is focusing its resources on high-value mRNA projects in oncology and other select areas.
• A strategic restructuring included a workforce reduction of approximately 30% to create a leaner organization.
• CureVac is advancing its second-generation mRNA backbone in proprietary non-respiratory infectious disease programs.
• A new program was initiated to address urinary tract infections (UTIs) with a lead candidate expected to enter Phase 1 trials in the first half of 2026.
• A Phase 1 study in patients with glioblastoma (CVGBM) is ongoing, with initial data expected in the second half of 2025.
• A clinical candidate for squamous non-small cell lung cancer (sqNSCLC) was selected, with IND and CTA submissions filed in the first quarter of 2025.
• As of December 31, 2024, CureVac had cash and cash equivalents amounting to 482 million.
• The company believes it can fund operating expenses and capital expenditure requirements at least through 2028.

Sentiment

Score: 6

Explanation: While the GSK deal provides financial stability, the restructuring and workforce reduction suggest challenges. The focus on oncology and new programs offers potential, but success is uncertain.

Positives

• Strategic restructuring provides financial resources and focuses efforts on high-value mRNA projects.
• Advancement of second-generation mRNA backbone in infectious disease and oncology programs.
• New program initiated to address urinary tract infections (UTIs) with a promising lead candidate.
• Ongoing Phase 1 study in patients with glioblastoma (CVGBM) shows promising initial data.
• Collaboration with GSK provides expertise and resources for influenza and COVID-19 vaccine development.

Negatives

• Strategic restructuring included a workforce reduction of approximately 30%.
• Reliance on collaborations for clinical trial design and execution.
• Uncertain regulatory pathway for mRNA products.
• Potential for competition from other companies developing similar therapies.
• Dependence on key personnel and potential disruption from their loss.

Risks

• Clinical trial delays or failures could prevent regulatory approval and commercialization of product candidates.
• Undesirable side effects from product candidates could delay or prevent regulatory approval.
• Inability to obtain or maintain intellectual property protection could limit commercial success.
• Reliance on third parties for manufacturing and clinical trials poses risks to product development.
• Failure to comply with obligations under license agreements could result in loss of intellectual property rights.
• Inadequate coverage and reimbursement for product candidates could limit market access.
• Disruptions at the FDA or other government agencies could hinder product development and approval.
• Cyberattacks or IT system failures could disrupt business operations.
• Strategic restructuring might not achieve intended outcomes.

Future Outlook

CureVac expects to fund its operating expenses and capital expenditure requirements at least through 2028, based on existing cash and cash equivalents.

Management Comments

• Tony Wood, Chief Scientific Officer, GSK: 'We are excited about our flu/COVID-19 programmes and the opportunity to develop best-in-class mRNA vaccines to change the standard of care.'
• Alexander Zehnder, Chief Executive Officer, CureVac: 'This new licensing agreement puts us in a strong financial position and enables us to focus on efforts in building a strong R&D pipeline.'

Industry Context

The announcement reflects a strategic shift in the competitive landscape of mRNA vaccine development, with CureVac focusing on specific therapeutic areas and GSK taking on a larger role in vaccine commercialization.

Comparison to Industry Standards

• Moderna and BioNTech/Pfizer are key competitors in the mRNA vaccine space, particularly in COVID-19 and influenza.
• The strategic restructuring and focus on oncology align with industry trends towards precision medicine and targeted therapies.
• The collaboration with GSK is similar to other partnerships in the biopharmaceutical industry, where companies combine expertise and resources to develop and commercialize new products.

Legal Proceedings

• CureVac is involved in ongoing patent litigation with BioNTech and Pfizer in Germany, the UK, and the US.
• Acuitas filed a motion to intervene and a motion to sever and stay the U.S. proceedings between CureVac and BioNTech with respect to four U.S. patents.
• Acuitas initiated arbitration proceedings against CureVac.

Related Party Transactions

• dievini Hopp BioTech holding GmbH & Co. KG is a major shareholder and has related transactions with CureVac.
• Molecular Health GmbH, a subsidiary of dievini, provides services to CureVac.
• Rittershaus law firm, where a former managing director of dievini is a partner, provides legal services to CureVac.

Stakeholder Impact

• Shareholders may experience dilution from future equity offerings.
• Employees are affected by the workforce reduction.
• Patients may benefit from new therapies developed through the focused R&D efforts.
• Suppliers may be impacted by changes in manufacturing plans.

Next Steps

• File an Investigational New Drug (IND) application in the second half of 2025, aiming to initiate a Phase 1 study in the first half of 2026 for the UTI vaccine candidate.
• Continue the dose-expansion Part B of the Phase 1 study for CVGBM, with initial data and a decision on advancing the program to Phase 2 expected in the second half of 2025.
• Advance the sqNSCLC clinical candidate, with IND and CTA submissions filed in the first quarter of 2025.

Key Dates

Keywords

mRNA, vaccines, oncology, infectious diseases, clinical trials, GSK, collaboration, intellectual property, regulatory approval, manufacturing, biopharmaceutical, CureVac, LNP, UPEC, CVGBM, sqNSCLC